Clinical Trials Sponsored by Moser, Helene

Total 2180 results

Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Celgene

Completed

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (GAH)

Myelodysplastic Syndromes | Multiple Myeloma | Leukemia Myeloid Acute | Leuklemia, Lymphocytic, Chronic

Spain
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Celgene

Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

Multiple Myeloma

India, Philippines, France, Portugal, Poland, South Africa, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Serbia, Slovakia, United Kingdom
Celgene

Approved for marketing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

Multiple Myeloma

United States, Canada
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Healthy

United States
Celgene

Completed

CC-223 and Ketoconazole Drug-Drug Interaction Study

Healthy Volunteers
Celgene

Completed

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer

United States, Spain
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China
Celgene

Completed

Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

Multiple Myeloma

United Kingdom, France
Celgene

Completed

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Celgene

Completed

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Small Cell Lung Cancer

United States, United Kingdom, Australia, France, Canada, Netherlands, Poland, Spain, Switzerland, Italy, Denmark, Hungary, Germany, Bulgaria, Czechia, Austria, Belgium
Celgene

Completed

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Advanced Solid Tumors

United States
Celgene

Terminated

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Pancreatic Neoplasms | Cholestasis

United States, Germany
Celgene

Completed

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Myelodysplastic Syndromes

United States, France, Spain, Australia, Czechia, United Kingdom, Italy, Germany, Greece, Poland, Russian Federation, Bulgaria, Sweden, Netherlands, Hungary
Celgene

Completed

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Small Cell Lung Cancer

United States, Netherlands, United Kingdom
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
Celgene

Active, not recruiting

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

Multiple Myeloma

Turkey
Celgene

Completed

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Healthy Volunteer

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Celgene

Completed

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Canada
Celgene

Completed

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Breast Neoplasms | Pancreatic Neoplasms

United States
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate

Healthy Volunteers

United States
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
Celgene

Completed

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-cell, Peripheral

Japan
Celgene

Completed

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Heathy Volunteer

United States
Celgene

Completed

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Healthy Volunteer

United States
Celgene

No longer available

Expanded Access for CC-2001

Other | Dermatologic

United States
Celgene

No longer available

Expanded Access for CC-4047

Multiple Myeloma

United States
Celgene

Completed

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 (AboundPS2)

Carcinoma, Non-Small-Cell Lung

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Celgene

Completed

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

Adenocarcinoma | Carcinoma | Non-Small Cell Lung Cancer | Carcinoma, Large Cell | Squamous Cell Carcinoma | Lung Neoplasm

United States
Celgene

Terminated

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

Crohn's Disease

Italy
Celgene

Completed

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Adult T-Cell Leukemia-Lymphoma

Japan
Celgene

Completed

AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)

Myelodysplastic Syndromes

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
Celgene

Completed

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Advanced Cancer

Australia
Celgene

Completed

Radiolabeled Study of CC-220 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Korea, Republic of, United Kingdom, Australia, Taiwan, Israel, Canada, Spain, China, Italy, Germany, Netherlands, Russian Federation, Belgium, France, Poland, Czechia, Austria
Celgene

Completed

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Celgene

Completed

A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms

Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia Myeloid Acute

Spain
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States

3

Subscribe